Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 27 for “"GLP-1 RA"”.

  1. Factors of Individuals that Sustained Weight Loss after Discontinuing a GLP-1 RA [poster]

    Glucagon-like peptide-1 receptor agonists (GLP-1) have been shown to be effective for weight loss; however, weight regain after discontinuation is common. This systematic review aimed to review characteristics that lead to sustained weight loss after discontinuing a GLP-1. A systematic search was …

    texas-state Repository record for Factors of Individuals that Sustained Weight Loss after Discontinuing a GLP-1 RA [poster] (opens in a new tab)

  2. Factors of Individuals that Sustained Weight Loss after Discontinuing a GLP-1 RA [paper]

    Glucagon-like peptide-1 receptor agonists (GLP-1) have been shown to be effective for weight loss; however, weight regain after discontinuation is common. This systematic review aimed to review characteristics that lead to sustained weight loss after discontinuing a GLP-1. A systematic search was …

    texas-state Repository record for Factors of Individuals that Sustained Weight Loss after Discontinuing a GLP-1 RA [paper] (opens in a new tab)

  3. The comparison of outcomes between metabolic bariatric surgery and glucagon-like peptide 1 receptor agonists (GLP-1 RA) after three years

    Background: Limited consistent literature is available on comparing the outcomes between metabolic bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonists (GLP-1 Ras). Objective: To compare the changes of weight, obesity-related comorbidity lab values, obesity-related medication …

    texas Repository record for The comparison of outcomes between metabolic bariatric surgery and glucagon-like peptide 1 receptor agonists (GLP-1 RA) after three years (opens in a new tab)

  4. Medication use patterns of weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-21s) in Texas Medicaid beneficiaries diagnosed with type 2 diabetes

    … glucagon-like peptide-1 receptor agonists (GLP-1 Ras) and sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) among Texas Medicaid beneficiaries with type 2 diabetes (T2D) using claims data from January 2018-March 2022. After applying eligibility criteria (adults aged 18-63 with a T2D …

    texas Repository record for Medication use patterns of weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-21s) in Texas Medicaid beneficiaries diagnosed with type 2 diabetes (opens in a new tab)

  5. Treatment Patterns & Clinical Effectiveness of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes

    … the greater efficacy and additional benefits for GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2is), reported in clinical trials for type 2 diabetes (T2D) patients, many fail to achieve similar clinical outcomes in the real world due to non-adherence, which potentially driven by …

    houston Repository record for Treatment Patterns & Clinical Effectiveness of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes (opens in a new tab) Embargoed until 2027-12-01

  6. GLP-1 receptor agonists and disordered eating: Clinical indicators and patient narratives

    Introduction: The use of the medication, GLP-1 receptor agonist (GLP-1 RA), for weight loss has increased exponentially in the United States over the past decade. The continuing rise in demand for the use of GLP-1 RAs for weight loss justifies the need to better understand the physical and …

    gvsu Repository record for GLP-1 receptor agonists and disordered eating: Clinical indicators and patient narratives (opens in a new tab)

  7. Gastric Point of Care Ultrasound (POCUS) in Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS)

    Purpose: This doctoral project evaluates the effectiveness of an educational intervention aimed at improving anesthesia providers’ understanding of Gastric Point of Care Ultrasound (POCUS) for assessing aspiration risk in patients on Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA). The goal is …

    arizona-thes Repository record for Gastric Point of Care Ultrasound (POCUS) in Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) (opens in a new tab)

  8. Identifying targets for increasing evidence-based use of novel cardiovascular medications in the Veterans Affairs System: Provider-level characterization

    Background: Novel therapies such as angiotensin receptor-neprilysin inhibitors (ARNI), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have well-established benefit for patients with heart failure (HF) and coronary artery disease (CAD), …

    washington Repository record for Identifying targets for increasing evidence-based use of novel cardiovascular medications in the Veterans Affairs System: Provider-level characterization (opens in a new tab)

  9. Detecting Renal Protective Effects Of Antidiabetic Medications Among Patients With Type Ii Diabetes Mellitus And Diabetic Kidney Disease

    … renal impairment is limited. Although some Randomized Controlled Trials (RCTs) for estimating the effect of these drugs on DKD have been completed for few antidiabetic medications, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i) and a few other antidiabetic drugs, the trials of …

    umn Repository record for Detecting Renal Protective Effects Of Antidiabetic Medications Among Patients With Type Ii Diabetes Mellitus And Diabetic Kidney Disease (opens in a new tab)

  10. Disparities And Barriers In The Utilization Of Glucose-Lowering Therapies For Type 2 Diabetes

    AbstractDisparities and Barriers in the Utilization of the Novel Glucose-Lowering Therapies for Type 2 Diabetes Diabetes mellitus affects approximately 38 million Americans, and 90–98% diagnosed with type 2 diabetes. It is the most expensive chronic disease in the United States, with an annual cost …

    yale Repository record for Disparities And Barriers In The Utilization Of Glucose-Lowering Therapies For Type 2 Diabetes (opens in a new tab)

  11. Όφελος των αντιδιαβητικών φαρμάκων στη μη αλκοολική λιπώδη νόσο του ήπατος

    … ανασκόπηση τυχαιοποιημένων ελεγχόμενων δοκιμών (Randomized Controlled Trials - RCTs) θα διερευνηθούν και παρουσιαστούν τα πλέον πρόσφατα βιβλιογραφικά δεδομένα σε σχέση με το όφελος των διαφόρων κατηγοριών αντιδιαβητικών φαρμάκων στην αντιμετώπιση της NAFLD. Αποτελέσματα: Συνολικά απομονώθηκαν …

    athens Repository record for Όφελος των αντιδιαβητικών φαρμάκων στη μη αλκοολική λιπώδη νόσο του ήπατος (opens in a new tab)

  12. Trends in Noninsulin Antidiabetic Medications in Patients with HIV and Type 2 Diabetes in North America, 2013 to 2021

    … has been increasing over the past decade in general population. We described the utilization of noninsulin antidiabetic medications among PWH with T2DM using data extracted from electronic health records (EHR) from 2013 to 2021. To compare the methods measuring the utilization of medications, we …

    jhu Repository record for Trends in Noninsulin Antidiabetic Medications in Patients with HIV and Type 2 Diabetes in North America, 2013 to 2021 (opens in a new tab)

  13. A cross-sectional study investigating the neurotrophic effect of GLP-1ra treatment on small fibre neuropathy in type 2 diabetes

    … complication of diabetes mellitus. However, strategies for preventing diabetic neuropathy, other than glycaemic control, remain poorly developed. One promising therapeutic target is the use of glucagon-like peptide-1 receptor analogues (GLP-1-ras), which exhibit neuroprotective effects in …

    essex Download PDF for A cross-sectional study investigating the neurotrophic effect of GLP-1ra treatment on small fibre neuropathy in type 2 diabetes (opens in a new tab) Embargoed until 2026-12-31

  14. Medication adherence among type 2 diabetes Texas Medicaid patients using basal insulin

    … adherence to three types of basal insulins: neutral protamine Hagedorn (NPH), first and second generation long-acting insulins. This retrospective study used Texas Medicaid claims from 1/1/2014-6/30/2017 for patients 18-63 years, with ≥2 basal insulin claims. Patients also had: ≥1 claim for an …

    texas Repository record for Medication adherence among type 2 diabetes Texas Medicaid patients using basal insulin (opens in a new tab)

  15. Emerging frontiers in type 1 diabetes: exploring novel therapies and their potential to transform care

    Incidence of type 1 diabetes mellitus (T1DM) is rapidly increasing and there are no cures for this disease. There is a significant cost burden placed on patients and healthcare systems due to type 1 diabetes mellitus. Most patients diagnosed are not meeting their glycemic targets with insulin …

    bu Repository record for Emerging frontiers in type 1 diabetes: exploring novel therapies and their potential to transform care (opens in a new tab)

  16. Glucagon Counter-Regulation to Hypoglycemia During Incretin-Based Therapy

    Incretin-based therapy is associated with low risk of hypoglycemia in type 2 diabetes mellitus (T2DM) possibly due to its glucose-dependency in stimulating insulin secretion and a sustained glucagon response during hypoglycemia. This is of special relevance when it is combined with insulin or given …

    lund Repository record for Glucagon Counter-Regulation to Hypoglycemia During Incretin-Based Therapy (opens in a new tab) Download PDF for Glucagon Counter-Regulation to Hypoglycemia During Incretin-Based Therapy (opens in a new tab)

  17. OPTIMIZING CARDIOVASCULAR OUTCOMES IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES: A MULTI-DIMENSIONAL ANALYSIS OF TREATMENT EFFECTIVENESS AND PERSONALIZATION

    … is the leading cause of death among kidney transplant recipients (KTRs) in the US, occurring approximately 3 to 5 times higher than the general population. This excess mortality persists despite medical advances in transplant care and cardiovascular therapeutics. Diabetes, whether …

    jhu Repository record for OPTIMIZING CARDIOVASCULAR OUTCOMES IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES: A MULTI-DIMENSIONAL ANALYSIS OF TREATMENT EFFECTIVENESS AND PERSONALIZATION (opens in a new tab) Embargoed until 2027-05-01

  18. Sex hormones, metabolic syndrome, and endocrine dysfunction in hidradenitis suppurativa: a literature review /

    Introduction: Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease that affects the intertriginous areas and results in painful nodules. Previous research has shown that there is an autoinflammatory component and that, particularly, metabolic syndrome (MetS) and androgens are …

    vilnius Repository record for Sex hormones, metabolic syndrome, and endocrine dysfunction in hidradenitis suppurativa: a literature review / (opens in a new tab)

  19. Advancing Lipid and Therapeutic Targets Structural Analysis Through Ion Mobility, Hydrogen-Deuterium Exchange, and Native Mass Spectrometry

    Despite the central role in chemical and biological analysis, routine and general mass spectrometry remains limited in resolving structural isomers, probing protein conformational dynamics, and characterizing heterogeneous oligomeric assemblies. These limit mechanistic discovery of biology and …

    tamu Repository record for Advancing Lipid and Therapeutic Targets Structural Analysis Through Ion Mobility, Hydrogen-Deuterium Exchange, and Native Mass Spectrometry (opens in a new tab) Embargoed until 2027-12-01

Page 1 of 2